Semaglutide vs Liraglutide

Reviewed by Gabriel Brocklesby · Last updated

Both are GLP-1 medications referenced in weight-management listings. Compare provider oversight, monitoring, and access models.

Semaglutide and liraglutide are GLP-1 receptor agonists used in weight management contexts. Clinics may offer one or both depending on availability and prescribing model. Use this comparison to evaluate provider governance and monitoring.

Semaglutide

A GLP-1 receptor agonist commonly referenced in weight management clinics.

Potential benefits

  • Widely adopted across clinic listings.
  • Often part of structured weight-management programmes.

Considerations

  • Requires prescriber oversight.
  • Eligibility varies by patient profile.
Best for: Comparing clinics with established GLP-1 pathways.

Liraglutide

A GLP-1 receptor agonist referenced in weight management and metabolic health listings.

Potential benefits

  • Often listed in clinic programmes with structured monitoring.
  • Common in metabolic health contexts.

Considerations

  • Requires clinician-led assessment.
  • Availability varies by region.
Best for: Evaluating clinics offering alternative GLP-1 options.
CategorySemaglutideLiraglutide
Directory contextInformational clinic and treatment comparison context.Informational clinic and treatment comparison context.
Common goalsCompare how clinics frame suitability, monitoring, and expected use cases.Compare how clinics frame suitability, monitoring, and expected use cases.
Guidance noteInformational listing only; suitability requires clinician review.Informational listing only; suitability requires clinician review.

Next step

Compare clinics offering these treatments

Use city pages and peptide-specific pages to move from general research into actual provider shortlists. That usually gives a better buying picture than comparing drug names alone.

Comparing GLP-1 options?

If you're deciding between semaglutide providers, comparing actual clinic offerings side-by-side is the next step.

Related clinics

FeaturedVerified

Menon Health

London, United Kingdom

Menon Health is a Mayfair-based peptide therapy clinic founded by Dr Mukil Menon, a GMC-registered physician and one of the first doctors to prescribe medical peptide therapy in the UK. Before establishing Menon Health, Dr Menon served as UK medical director at Koniver Wellness, launching the clinic at Soho House London. He continues to practise within the NHS alongside his private consultations, ensuring his protocols stay grounded in current medical standards. The clinic offers doctor-led, prescription-based peptide therapy alongside regenerative cell complex treatments, bloods and diagnostics, and IV therapy. All formulations are sourced from GMP-certified, EMA-regulated pharmacies and dispensed as pre-filled pens, vials, or multi-peptide syringes — Menon Health's approach to combining multiple peptides in a single dose is designed to improve precision and patient adherence. Based at 64 North Row in Mayfair, London, Menon Health serves patients across the UK, Europe, Canada, and the United States, with consultations available in person or remotely.

In personRemoteFrom £195Virtual consultations
View ProfileSend EnquiryCompare

Conclusion

Both are clinic-dependent choices. Focus on prescriber credentials and monitoring standards when comparing providers.

Related peptide pages

London treatment pages

US city pages

For clinics

Are you a clinic?

Get featured on this page and reach patients actively looking for peptide therapy, GLP-1 treatments, recovery support, and longevity care.